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Meeting Report
An international symposium on ovarian cancer, organised
by the Universities of Glasgow and Strathclyde, was held in
Glasgow from September 11-13, 1985
Rapporteur: A.P. Simmonds
Cell Laboratory, Biochemistry Department, Royal Infirmary, Glasgow G4 OSF, UK.
The programme was divided into several distinct
categories: an analysis of the problem and
experience of ovarian cancer management from
several centres including surgical staging and
cytoreduction, the place of second-look laparotomy
and the successes and limitations of chemotherapy
and alternative forms of management. Ovarian
cancer pathology was reviewed for both epithelial
and germ cell tumours and prognostic factors
discussed. Laboratory models for ovarian cancer
included tumour culture and drug sensitivity
evaluation, the influence of fe&der cells and the
analysis of resistance and the use of the nude
mouse as a model for monoclonal antibody
therapy. Tumour markers were reviewed, their
detection with antibodies and clinical usefulness
then discussed. Other laboratory studies included
investigation of receptor status, expression of MHC
products, the development of monoclonal
antibodies and investigation of drug concentrations
surrounding tumour cells in vivo.
C.N. Hudson reviewed the extent of the problem in
ovarian cancer management and presentation by reference
to a North West Thames prospective study of > 1,000
patients: the natural history and therapeutic practice
between 1973 and 1980. He pointed out that most patients
received diagnosis and follow-up with general
gynaecologists with no interest in malignancy and whose
experience will be limited.
Within the study, the histology was unremarkable,
although the incidence of endometrioid cancer was high,
that of metastatic disease lower than anticipated, but age
was found to be an important variable with a bias in
favour of stage and grade found in younger cohorts. Few
patients presented with menstrual disturbance or post-
menopausal bleeding, abdominal swelling, abnormal or
inappropriate hormone production or pleural effusions.
Neurological, vascular or cutaneous features were rare,
but there was a disproportionate incidence of indigestion
as a factor in early disease.
Committee members: A. Belfield, A.D.T. Govan, J.H.
Kennedy, D.R. Pledger, A.P. Simmonds and W.H.
Stimson.
There was also a clear distinction between early and
late progression of disease, the former attributed both to
unrecognised understaging and to conservative surgery to
conserve reproductive function. Less than 50% patients
with advanced disease had sub-total hysterectomy,
indicating far from maximal cytoreduction, and the total
14% survival was far worse than that from recognised
therapeutic centres, indicating a lack of understanding as
to what might be achieved by effective surgery and follow-
up. It was stated that maximal cytoreduction should be
achievable in the majority of Stage III patients and, until
it was understood that ovarian carcinoma was only
inoperable in the upper abdomen and then infrequently
so, patients were unlikely to obtain benefit from other
advances in treatment. Raising awareness of this amongst
clinicians and medical undergraduates was therefore a
priority. Questioned by J. Berlie about a control study to
assess epidemiology, he confirmed that this was done for
200 patients and in answer to F. Lawton stated that
gynaecologists had learnt little in terms of changing
surgical practice over the period of study. R.C.
Knapp commented that tumour biology might influence
the surgeon's ability to perform cytoreductive surgery and
A. Govan confirmed that some tumours stimulate dense
fibrous tissue growth. B. Ward added that there was a
relationship between diploid tumours and operability. In
answer to A. Talerman and J. Baak, Prof. Hudson
confirmed that the tumours studied were graded according
to the worst area found and that all were studied by the
Regional Pathologist.
Complementary to this, M. Kaufmann presented a
study from Heidelberg involving a 25 year review of 370
epithelial ovarian carcinomas. There was clear evidence
that low stages are becoming rarer and that Stages III and
IV are on the increase. Survival by stage followed the
usual trend but the advent of cis-platinum, together with
more aggressive surgery, has had a marked influence on
survival. For Stage IV patients, where the younger cohorts
fared worse there was no difference in outcome between
chemotherapy alone or combined with radiotherapy
whereas aggressive chemotherapy, followed by
radiotherapy, has had a marked influence on Stage III
survival. Of 87 patients, III and IV, 41 had second-look
laparotomy and 18% had no microscopic disease. Five
year survivals were now 33% compared to 15% for less
aggressive management. It was clear that this
improvement was due both to more accurate staging
procedures and to risk-adapted aggressive therapy. B.
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Ward asked about the malignant potential of the tumours
studied and A. Simmonds submitted that in her
experience, behaviour of primary tumours in culture had
not yet been correlated with stage of disease, prognosis or
tumour aggression. There followed a vigorous discussion
about the benefit of second-look procedures with B.-U.
Sevin commenting that he had cured Stage IV patients
with aggressive surgery by looking for tumour while K.K.
Chan doubted the benefits of such follow-up, citing
similar survivals in NED and residual microscopic disease
patients. I. Rocker commented that although we must
have the knowledge derived from 'second-look', many
surgeons will refuse to do it.
The place of surgery in the treatment of ovarian cancer
was presented by B.-U. Sevin with the controversial
aspects being reviewed by K.K. Chan. The former
outlined the functions of surgery as diagnosis, correct
surgical staging and debulking. The surgeon must look for
tumour until it is found and the residual tumour volume
must be reduced to a minimum. Since tumour nodules
larger than 0.5cm may not receive drug due to poor
penetration and since the presence of hypoxic areas makes
radiotherapy insufficient or ineffective, it is clear that
primary surgery has the greatest influence on prognosis.
Gross tumour must be removed without rupture, washings
taken and any remaining masses defined and recorded
diagrammatically. The retroperitoneal space and the pelvic
and para aortic lymph nodes must also be investigated. A
typical debulking laparotomy was described starting with
a mid-line incision. A valid assessment of macro and
microscopic disease must be made by examining the upper
abdomen using a light, by palpation and by washing. A
radical oophorectomy and retroperitoneal resection should
be performed and Dr Sevin outlined the use of a variety
of automated stapling equipment which can cut, ligate
and staple and which is particularly valuable in sub-total
omentectomy and resection of bowel/colon as part of
debulking. Some patients might additionally benefit from
resection of the rectosigmoid. The value of radical surgery
was again stressed by figures indicating that those patients
(20%) with microscopic disease at 'second-look' had 96%
2 year and 71% 5 year survivals irrespective of therapy.
Those patients with negative second-look had 85% 5 year
survival. Patients with less than 0.5cm residual disease
had whole abdomen irradiation and may also have i.p.
cis-platinum and cytosine arabinosde and i.p. or systemic
immunotherapy including interferon. Dr Sevin replied to
questions from B. Ward, N. Saunders, F. Lawton and I.
Rocker by commenting that colostomy is unneccessary
when staples are used, that anastomatic leakage is not a
problem, but that, although mortality is low with this
surgery, hepatic and splenic reduction will not benefit
patients. He further commented that only 20-30% of
patients have bulk disease following primary laparotomy
in contrast to c. 50% in UK, and that this is found
primarily in diaphragm and root of small bowel
mesentery. There was further discussion about the
feasibility of upper abdominal radiotherapy, if the pelvis
had been successfully cleared, provided that lung fibrosis
and liver damage were avoided.
K.K. Chan gave a review of the place of surgery by
commenting on the lack of consensus as to the
appropriateness of certain procedures. He commented that
the commonest malignancy of the ovary is secondary and
that possible primary sites must be investigated.
Understaging was still a problem (>50% for Stage II)
when surgery was not employed, but there were times
when CT scans were more accurate than surgery in
picking up hepatic metastases. Staging could be improved
by the greater use of non-invasive techniques prior to
surgery, although success in debulking a tumour might
reflect its biological characteristics as well. The most
controversial aspect of surgery is the second-look, the
theoretical benefits of which are as a diagnostic tool, the
assessment of response to therapy, particularly as further
biopsies may be obtained and as an aid to prognosis and
decisions concerning therapy. Seventy-three to 90%
patients relapse after a surgical CR and since a negative
second-look cannot be taken as an assurance of cure, it
cannot therefore be used as an end-point for
chemotherapy. It could, however, be argued that the
discomfort of second-look is offset by a clear survival
advantage. A Birmingham study had been unable to show
survival benefit of total macroscopic clearance of tumour
at second-look. Patients with residual macroscopic disease
after initial laparotomy were randomised to (i) cis-
platinum (responders to have second-look and total pelvic
and abdominal irradiation) (ii) chlorambucil and second-
look and (iii) chlorambucil alone. Initial results fail to
show a difference in survival in the 3 arms and other
studies have shown that the second-look did not produce
an advantage in treatment other than the reassurance of
improved prognosis. Further surgery may however, be
advantageous for patients having PR to chemotherapy or
initial sub-optimal resections.
The question of salvage surgery was also mentioned
since 25% patients with advanced disease present with
intestinal obstruction. Although surgery at this stage
carries an operative mortality of 4-14%, decisions
concerning surgery may be made using a risk-score system
and conservative management may be all that remains.
However, if there is no evidence of tumour recurrence,
surgical exploration is mandatory and beneficial. If
tumour is present and little chemotherapy has been
received, then aggressive chemotherapy is worth trying,
but in patients who have received adequate chemotherapy,
the palliation possible from what may be a prolonged and
unpleasant death is sufficient justification.
J. Baak questioned Mr Chan about the risks of second-
look procedures but these were low resulting in morbidity
rather than mortality. N. Saunders asked about the
possibility of surgery on irradiated patients and what
influence on survival was found by surgery for
obstruction. Survival was poor but palliation good.
Further contributions on the value of surgery were
made by L. McGowan and I. Rocker. Prof. McGowan
analysed the question of mis-staging as evidenced by
practice patterns in the Metropolitan Washington DC
area. For 291 patients, evaluation procedures were missed
out most frequently by general surgeons, frequently by
gynaecologists and rarely by gynaecological oncologists.
This resulted in correct staging in only 27% and 46% of
patients when performed by the first two groups, but 82%
by the specialised oncologists. Clearly, treatment failures
for presumed early ovarian cancer can be attributed to
incomplete evaluation particularly when percentage
distribution of the 4 major stage categories in this series is
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I. Rocker reviewed changing practice patterns in South
Wales. An earlier study had shown that only 10-15% of
patients had received radical primary surgery but that
survival in Stage III and IV patients receiving radical
surgery and cis-platinum therapy is now 77% in the short
term and some second-look procedures are allowing
debulking surgery. However, in view of the fact that
second-look confirmed clinical response in only 28/54
patients, he questioned whether such a procedure was
worthwhile.
K. Lloyd presented a review of tumour markers for
epithelial ovarian cancer and their detection with mouse
monoclonal antibodies. Markers are useful in gaining
understanding of the genetic make up of normal
epithelium and in recognising the molecular characteristics
of malignant cells. New antigens may be identified in 3
stages (i) mice immunised with ovarian tumour cell lines
may generate antibodies using hybridoma technology (ii)
these may be screened with immunoperoxidase to look for
cytoplasmic and secreted antigens in order to pick up
potential serum markers (iii) where mice are immunised
with fresh ascites, the hybridoma supernatant may be
screened against normal tissues and ovarian tumours.
Antigens found to date have a wide spectrum of
distribution e.g. MH99 being characteristic of all epithelial
cells regardless of origin and MH941 restricted to
secretory epithelia is unreactive with normal ovarian
epithelia, but stains epithelia surrounding ovarian cysts
and many ovarian carcinomas. MT 334 reacts only with
colonic crypt cells among normal tissues examined but is
found on a proportion of cell lines and other epithelial
tumours of lung. Ovarian tumours are invariably positive,
benign as well as malignant, while less than 10% of sera
from ovarian cancer patients had elevated levels. The
secreted antigen 116 is found exclusively in culture
medium and is impossible to detect on the cell surface,
but appears to be confined to ovarian tumours. The Y
antigen is an example of the blood group antigens
differentially expressed on epithelia of different kinds and
its expression is therefore related both to the patient
blood type and secretor status. Conclusions from this
study are that antigens restricted to tumours are rare, but
that the use of antibodies in imaging and radiolocalisation
has been achieved with CEA and milk fat globule protein
and work in progress is exploring the use of lectin, drug
and isotope conjugates.
R. Knapp commented that panels of antibodies would
be necessary in any likely therapy, as there can be change
or loss of antigens as metastases develop. In answer to A.
Talerman concerning the frequency of antigen expression
in metastases, Dr Lloyd said that it had only been studied
in blood group antigens where metastases and most
malignancies do express them although such expression
might be lost progressively.
R. Knapp opened a long session on CA125 antigen by
reviewing its distribution and properties and making a
clinical evaluation of the CA125 immunoradiometric
assay. He stressed that, although 'normal' tissues are
negative, benign, borderline and malignant tumours may
be positive, therefore the antigen is not specific to ovarian
cancer. Using the two cut-off points of 35 and 65 Uml-1,
there is a spectrum of false positives in that 1% of
apparently healthy subjects are positive. Levels may also
be elevated in endometriosis, fibroids and pelvic
inflammatory disease. It is elevated also in acute
diverticulitis but not in the pneumonia subjects studied.
In a review of the use of the assay, clear areas were
discussed (i) can it detect ovarian cancer in screening? (ii)
whether it can be used in diagnosis (iii) whether it can do
away with 'second look' by both providing evidence of
residual disease and predicting clinical outcome and (iv)
whether it can predict failure of therapy.
The assay cannot differentiate benign from malignant
pelvic masses, but on patients with known malignant
disease, assays were taken prior to surgery and up to
second-look. Levels remained elevated following poor
cytoreductive surgery but where surgery was maximal and
they remained <35Uml-P up to second-look, this was
negative. Where levels showed a gradual rise up to
second-look, this was positive. Reduction of marker to
<35Uml- I over a 3 month period was an early indicator
of successful therapy. For borderline tumours CA125
levels rose in some patients 6-8 months before developing
a clinical recurrence. With respect to avoiding second-look
procedures, all patients with assay levels >35Uml- had
tumours even when clinically and radiologically negative;
there were no false positives. However, patients may still
have tumours if assay levels are less than 35Uml-1.
As a prognostic indicator following second-look, CA125
levels increased in patients who fared badly, but a single
assay at second-look was only of value for one year i.e.
>35 Uml-1 signified a poor outcome and such levels
occurred 3-4 months prior to clinical or radiographic
recurrence. Similarly, it is suggested that second-look
could be avoided if assay levels are >35Uml-1, but it is
suggested that, where patients are clinically negative but
surgically positive, the assay should be done every 4
months for 2 years and those negative overall should be
followed at 6 month intervals. In answer to a query about
the two levels 35 and 65 Uml-1, Prof. Knapp pointed out
that 65 is the limit for detection but the 35 value is more
sensitive for evaluations. Mr Adams queried the effects of
surgery on CA125 levels; these were elevated in patients
with perforated ulcers but levels fell back. C. Selby
commented that this was also true for a benign thecoma
prior to surgery. C. Naylor was interested in the levels
found in pregnant women; 50% of patients had elevated
levels in the first two trimesters, these then fall in the
third.
Contributions on the use of CA125 in different centres
in the UK were made by R. Leonard, R. Fish and C.
Selby. Dr Leonard presented a study of Stage III and IV
patients where clinical correlations were made on an
average of 4 assays pre and post treatment. Sixty percent
of patients had a positive assay with clinical disease, but
37% were false negatives. Twenty-two of 41 patients had
consistent results i.e. negative in the absence of disease,
confirmed by second-look, and positive when disease was
present, whereas 5 had persistent false negative results
with palpable tumour. A further 2 patients had normal
CA 125 levels just prior to death from advanced disease.
The CV at the assay level 20-70Uml-1 was 20-50%.
R. Knapp commented that trends in curves are as
important as individual results and groups of patients who
do not shed antigens may do so at a later stage in disease.
R. Fish had correlated CA125 levels with tumour
burden pre-treatment and examined assay usefulness for
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benign conditions there was no elevation above
35Uml-'. There was a trend towards increase with stage
in malignant patients and marked elevations when tumour
burden was greater than 10cm. Of 28 patients elevated
pre-treatment, 12/14 positive at secondlook had
consistently high levels whereas 2 were in the normal
range. Conversely, of 4 patients NED at second-look, 2
were elevated. R. Knapp concurred that patients NED
at second look had elevated levels of CA125, but all had
relapsed within one year suggesting the assay was more
accurate than the second-look evaluation. In answer to R.
Leonard concerning the avoidance of second surgery, it
need not be done if the CA125 levels are elevated or
rising. B.-U. Sevin felt strongly that second-look should
not be avoided and that the failure to find disease at this
time was due to ineffectual evaluation, hence the relapse
of patients NED.
C. Selby had investigated 12 groups of patients with
and without malignant ovarian disease. Six of 12
categories demonstrated elevated CA125 levels but there
was a clear distinction between those with ovarian
malignancy and other malignant disease in all but two
cases. Eighty-seven per cent of patients had values
>65Uml-1. In post-operative monitoring of treatment,
there was good assay correlation with both regression and
progression. There might also be value in screening a
selected population - 80% with malignant ovarian disease
might be detected. C. Hudson commented that immune
complexes in circulating CA125 might be responsible for
preterminal fall levels and B.-U. Sevin pointed out
that protein metabolism in terminal patients was grossly
abnormal. J. Heron presented work from France on the
comparison of 2 markers CA125 and galactosyl
transferase (GT). For 113 patients there was a clear
distinction between ovarian malignancy and other groups
when GT was evaluated; the one control patient with
elevated levels was found to have a benign ovarian cyst.
Following chemotherapy, there is a striking drop in serum
GT activity and correlations were made between this and
clinical outcome. This correlation was found for 13
patients; there were also 16 false negatives and 7 false
positives during the clinical course. For 30 cases, there
was a parallel variation of the 2 markers. For 5 patients
only GT reflected accurately the clinical course and
CA125 was of no value, whereas a further 3 patients
exhibited the converse pattern. A further study of 29
patients showed the same pattern and it was felt that both
markers should continue to be investigated, particularly as
the range of variation of GT is low, creating difficulty in
interpretation. Three patients with surgical CR had
elevated GT levels which have remained unexplained.
A. Belfield pointed out that these could be evaluated in
infection and it was suggested by D. Pledger and C. Selby
that any 'hook' effect could be avoided by serial dilution
of samples.
P. McLaughlin then presented a study of placental
type alkaline phosphatase (PLAP) in ovarian tumours.
Three murine monoclonal antibodies have been developed
at ICRF and 1231 labelled H317 was used both for
radioimaging to detect recurrence or metastases and to
detect plasma and tissue section PLAP. Thirty to 40% of
malignant ovarian tumour patients had plasma PLAP and
20% of benign tumour patients also, whereas 120 controls
were negative. Most malignant ovarian tissue shows
staining for PLAP and benign little or none but both
malignant and benign may be equivocal.
Patients were radioimaged 1-4 years post primary
surgery with 123I-H317 administered IV and scanned
with a gamma camera. Of 18 patients, 12 showed focal
increased abdominal uptake. In 9, this confirmed
suspected recurrence and in 2 cases revealed unsuspected
tumour. Of 6 normal scans, 5 were confirmed and one
had tumour which failed to image. Imaging results did not
correlate consistently with original fresh tissue PLAP
positivity. In answer to K.K. Chan, Dr McLaughlin could
not give a value for the smallest tumour detectable by this
method, but in one case the imaging had picked up
multiple bowel seedlings where CAT scan was clear.
A. Talerman commented that the marker was good for
serous tumours.
J. Baak introduced the session on ovarian
pathology by discussing prognostic factors in ovarian
tumours including the borderline sub-type. Histo-
pathological criteria should be routinely included in the
therapeutic decision-making process since, despite recent
upstaging for Stage 1 patients, the 5 year survival figures
for this group have not shown the expected increase.
Clearly tumours must be sampled adequately and grading
must be more clearly defined. In an investigation of
interobserver variation in grading, thought to be between
25-40% between different pathologists, 200 random cases
of epithelial ovarian carcinoma were graded blind by 4
pathologists and repeated at 6 month intervals. Overall,
intraobserver complete agreement was poor and complete
agreement was found in only 25-30% cases in
interobserver discussion. Prognostic criteria as evidenced
by 5 year survivals showed variations of between 80-
100% but there were percentage grade differences in the
different series. The worst variation, 45-80%, was found
for well differentiated tumours, but for poorly
differentiated tumours an acceptable degree of variation
was found between the 4 pathologists and borderline
tumours had the best prognostic criteria. Since such
prognostic information must be available in the
microscopic image, techniques of quantitative pathology,
morphometry, may be used to detect minor differences or
changes which escape the pathologist. Using static
cytometry - where DNA ploidy is evaluated and DNA
histograms constructed, patients with long term survival
have a high proportion of histograms Class 1 or 2 and
those with poor prognosis Class 3 or 4. However, the
reproducibility of this method is not good and the use of
flow cytometry may reduce variation. Since a prospective
study in the Netherlands failed to substantiate the
suggestion that diploid tumours have a better prognosis,
the technique of interactive morphometry on H and E
stained slides is now used routinely. In this method,
nuclear areas are measured and the information stored in
microcomputers. There are clear differences between the
different grades.
Using this technique Prof. Baak was able to establish in
a blind trial that this could select survivors and it is hoped
to automate this test. In answer to M. Moore and A.
Talerman, it was confirmed that the technique could be
used at any stage in disease, but that the problem of
representative sampling would always remain. B.-U. Sevin
asked about changes following chemotherapy: mitotic
rates were considerably decreased.MEETING REPORT 447
A. Talerman gave a comprehensive review of germ
cell tumours of ovary. They are the second largest group
of ovarian tumours comprising 20% of ovarian
neoplasms. They are found in proportionately greater
numbers in Africa and Asia, 8-10% are malignant and
they occur mainly in children and adolescents. The
malignant tumours are usually large, solid and unilateral
and metastasize by the lymphatic and haematogenous
routes. The dysgerminomas are large tumours which grow
rapidly and metastasize quickly. Although highly
malignant, their prognosis is good, because surgery is
usually effective and in the case of recurrences (20%) the
tumour may be readily treated by radiotherapy and
chemotherapy. The mesonephromas, however, are
radioresistant but combination chemotherapy is highly
effective, particularly as patients usually present with
metastases. Alpha FP remains a good tumour marker.
Other tumour types discussed were the chorocarcinomas,
mature cystic teratomas with malignant transformation in
which the prognosis is poor, monodermal tumours,
carcinoids and gonadoblastomas. Prof. Talerman stressed
the enormous benefits brought about by modern
chemotherapy and the use of tumour markers which can
be used for diagnosis, early detection of metastases and
recurrences and for monitoring the efficacy of
chemotherapy. There was some discussion about
chemotherapy regimes, C. Hudson preferring to keep cis-
platinum for relapsing patients and G. Blackledge also
wishing to avoid alkylating agents, both to retain fertility
and to avoid leukaemogenesis.
The question of chemotherapy, its achievements and
limitations was reviewed by E. Wiltshaw opening the
session on drug management. Ovarian cancer was the first
epithelial tumour to show a definite response to the
cytotoxic drugs which have now been used for the last 20
years. When alkylating agents were first used, they were
given in low doses, orally, over a long period of time and
the poor remission rates obtained, together with the side
effects, rendered their use unjustifiable. More recently,
with the advent of cis-platinum, particularly when used in
combination with other agents, significantly better
remission and survival rates have been obtained. This has
been due in part to the higher doses used, but also to the
minimisation of side effects by the adequate monitoring of
biochemical parameters, the protection of the kidneys by
salination of the IV infusions and to the higher standards
of nursing care. It remains a fact, however, that 40% of
patients are resistant to their first line therapy. This may
be due to kinetic, biochemical, pharmacological or tumour
cell dormancy factors, but resistance may also appear as a
permanent genetic change. If the first line therapy consists
of chlorambucil, melphalan or cyclophosphamide and the
second line drugs are the same or other alkylating agents,
resistance will be manifest in 95-100% of cases. Similarly,
if an alkylating agent is given followed by cis-platinum or
cis-platinum followed by another alkylating agent,
resistance will also be seen in 95% of cases.
Attempts to reproduce the anticancer effects of cis-
platinum without the toxicity have led to the development
of analogues such as carboplatin, JM-8. In ovarian
cancer, this has not yet been proved as useful and the
higher percentage of cross-resistance (80%) observed
between this and cis-platinum gives cause for concern. No
such figures on cross-resistance are yet available for CHIP
(JM-9), either with cis-platinum or JM-8.
Notwithstanding these disadvantages, modern regimes
of chemotherapy have had a pronounced effect on the
clinical outcome for patients with advanced ovarian
cancer. If patient sub-groups are selected carefully, and
the therapy administered so as to maximise anti-tumour
effect while minimising toxicity, then considerable benefits
will result, both in remission rates and survival figures.
Complementary to this review, papers reflecting
experience of clinical trials using platinum in Dublin,
Cardiff, Birmingham, Manchester, Southampton, Glasgow
and French Cancer Centres, were then presented.
J. Fleming reviewed a protocol whereby patients were
treated with combination cis-platinum and treosulphan at
monthly intervals for 12 months (Stages II, III and IV)
and response evaluated by second look. Twenty-five of 41
patients were clear at second-look. Fifty-two per cent of
patients had complete remission from 5-63 months
(median 26.5 months) excluding those who refused. Seven
patients in CR subsequently relapsed. Three year survivals
were Stage I - 79%, Stage II - 77%, Stage III - 37%,
Stage IV - 0%.
M. Adams had conducted a randomised trial of cis-
platinum versus JM-8 as first line therapy in advanced
disease and had compared toxicities. Patients were
randomised to cis-platinum or JM-8 as single agents
monthly for up to 5 courses, being crossed to the opposite
analogue if there was tumour progression or residual
tumour after 4 courses. Responses in 14 patients evaluated
to date have been similar, but JM-8 appears less toxic, as
there was reduced vomiting and no renal or ototoxicity.
F. Lawton had used single agent cis-platinum on 153
patients for 5 courses. One hundred and eleven of these
patients were Stage III. Median progression free interval
was 12 months and overall survival was 17.5 months.
Seventy-two patients with sub-optimal surgery were
randomised to second-look. Some were withdrawn due to
disease progression, others had bulk disease at second
look and a third group had disease converted to
microscopic or minimal by chemotherapy. Patients with
mucinous tumours were much less likely to achieve this
latter state; eight per cent compared with 42% of serous
and 38% of undifferentiated. Poorly differentiated
tumours were also more likely to undergo chemical
debulking, demonstrating clearly that favourable sub-
groups in terms of tumour pathology and grade can
obtain substantial benefit from chemotherapy.
J. Wagstaff had conducted a non-randomised study
comparing cis-platinum, CHIP and CBDCA, each in
combination with cyclophosphamide for 6 cycles in Stage
III and IV patients. Response rates at preliminary
evaluation are similar, but toxicity profiles markedly
different. There has been no renal impairment, less
auditory and neurological toxicity and diminished
vomiting episodes associated with CHIP and CBDCA.
However, diarrhoea and depression of white cell and
platelet count are a feature of the use of these analogues.
J. Sweetenham had compared a cis-platinum
combination with adriamycin and cyclophosphamide with
single agent chlorambucil in 89 patients with Stage III and
IV ovarian carcinoma. Second look laparotomy was
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disease. Seventy six per cent of patients had unfavourable
post operative tumour bulk. Response rates to the
combination and chlorambucil were 68% and 26%
respectively; a significant difference. However, there was
no significant difference in median or overall survival in
those patients with bulky disease, stressing again the
importance of adequate cytoreductive surgery.
J. Berlie and his group had compared two
combination protocols using cis-platinum for 150 patients
with Stage II, III and IV disease. The first combination
used platinum with adriamycin, VM 26 and cyclo-
phosphamide; in the second, hexamethylmelamine was
substituted for VM 26. Second look was performed on
75% of 116 evaluable patients (58 from each group) and
no significant differences found between the two
protocols. Seventy seven complete responders were found
overall. Responders were further randomised to whole
abdominal irradiation or a continuation of aggresssive
chemotherapy for 16 months. The results from such severe
treatment were not justified by the benefits and this latter
policy of treatment has now been discontinued.
M. Harding examined the efficacy of cylophosphamide,
adriamycin and cis-platinum in advanced ovarian cancer,
pointing out that, pre-platinum and adequate staging,
prognosis in this disease was poor, even for stage Ic
patients. Fifty-nine patients received this regime, of which
49 were subsequently evaluable. Fourteen had surgical CR
and 35 had PR surgically confirmed. Overall, few had
drug resistant disease, but toxicity resulting in alopecia
and nausea and vomiting was universal. There were no
problems, however, with myelosuppression or
nephrotoxicity. Survival by Stage was not statistically
significant; median survivals for Stage II, III and IV were
23, 17 and 13 months respectively. For patients with
residual disease after primary surgery, 16 months survival
was average while 26-40 month survivals were found with
cytoreductive surgery and this was found to be significant
in multivariate analysis.
Survival correlated with response; median survival for
CR not being reached at 44 months. For PR it was 20
months and for stable/progressive disease 11 months.
However, with a minimum 2 years follow up from CR,
only 4/10 Stage III patients remain disease free, the
median time to relapse was 33 months. Therefore it is
clear that, while effective surgery and chemotherapy
increase the number and duration of remissions, the
majority of patients cannot be cured if survival beyond 30
months is used as an end-point.
There was a vigorous discussion following these
presentations, in particular about the value of second look
surgery. There was general agreement that chemotherapy
should be given even in CR as these patients do relapse
eventually. It is possible that i.p. chemotherapy or total
abdominal irradiation will improve these figures.
The role of whole abdominal radiotherapy was reviewed
by S. Ludgate who commented that, although adjuvant
therapy is indicated post surgery, the possible use of
radiotherapy has not been established, since there is a lack
of well controlled randomized trials. There is some
suggestion that it is only of value in Stage II disease,
being harmful in Stage I and inappropriate in Stage III.
In this study, 84 patients with no residual macroscopic
disease post primary surgery were randomized to
observation or whole abdominal and pelvic irradiation.
Patients were substratified for tumour differentiation,
stage and age. Where outcome was checked against
tumour grade, 100% of Stage I patients were alive at 5
years irrespective of treatment, while Stage II patients
demonstrated a clear statistical difference in favour of
treatment, and for Stage III patients no difference was
observed. In summary, radiotherapy has a place following
effective cytoreductive surgery in Stage II patients with
negative lymphograms and normal LDH levels.
Unhappily, this constitutes only some 27% ofpatients.
The role of immunotherapy was discussed by C.
Nowotony. Its aim is to restore or activate immune
function, although its usefulness has not yet been
established in clinical practice. A streptococcal
preparation, OK432, was administered i.p. to patients
with ascites, who had already become resistant to
radiotherapy and chemotherapy. Doses were increased to
give maximal effects and for 4/7 patients this resulted in
complete disappearance of ascites and for 2/7 a reduction
in ascites volume. Three patients are still alive, one 14
months post-treatment. A reduction in tumour mass was
also seen, together with reduction in plating efficiency of
ascitic cells. There was clear augmentation of natural
killer cell activity and autologous cytotoxicity and a
reduction of suppressor cell activity of the peripheral
blood and exudate derived effector cells. These
pronounced results had not been expected and, in answer
to questions, Dr Nowotony emphasized that reduction in
tumour size had been clearly seen on ultrasound but that
CA125 levels remained high; the patients were not tumour
free but had stable disease.
A number of laboratory studies as an aid to diagnosis
and management of ovarian cancer were presented. R.
Leake had evaluated oestrogen and progesterone status of
45 patients with epithelial ovarian tumours. An
investigation of 105 normal ovaries had shown that 60-
70% are ER and PR positive and it has been suggested
that ER and PR positive patients have a better chance of
survival and that it is a good prognostic indicator.
Assays were carried out on both soluble and nuclear
fractions from each biopsy. Seven of 45 (16%) patients
were positive for both receptors; 10/45 (22%) were
positive for progesterone receptors and the situation
PR+ve (ER-ve) was uncommon. Patient follow up indi-
cated that those dying within a few months are receptor
negative while those surviving 15-18 months are positive.
There is therefore a clear survival advantage in receptor
positive status, but the measurement of ER alone has little
value. The 15% of patients in this category could receive
progestin therapy; one patient who received it had a CR
and has survived 15 months to date. In answer to
questions, Dr Leake confirmed that the highly
differentiated tumours are receptor positive, and that the
problems of contrasting normal, benign and malignant
tissue in the ovary can be resolved by using antibodies to
detect the number of malignant epithelial cells relative to
the total.
M. Moore presented a study of the expression of MHC
products and leucocyte differentiation antigens in normal
ovary and ovarian carcinoma. Two of the classes of MHC
molecules are: I HLA-A, B,C - expressed on virtually all
nucleated cells and II HLA-D, largely confined to cells of
the immune system but which may also be found
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possibility that they may have a role in autoimmune
phenomena and in tumour cell recognition in the
autocrinous host. If target cells lack Class I, they may
not be recognised by cytotoxic T cells and MHC status is
important in the context of conventional immunological
recognition.
An immunohistological investigation of normal ovary
and ovarian tumours was described using monoclonal
antibodies on fresh tissue by conventional immuno-
cytochemical techniques. Ten epithelial malignancies
examined were Class I negative, but this feature is not
specific to ovarian carcinoma, having been found in other
tumours. Class II products were detectable in 4/8
tumours, the pattern of staining being either uniform or
heterogeneous. The implication from this early study is
that lack of Class I products favours the tumour at the
expense of the host by removing neoplastic cells from
immune recognition, but it is not yet possible to relate
MHC expression to prognosis.
A further study investigating monoclonal antibodies
and their possible use in detecting residual or recurrent
disease was presented by F. Al-Azzawi. Lack of specificity
for ovarian tumour antigens has been a problem. In an
earlier study, immune complexes from pregnancy sera
were found to react with ovarian cancer cells and
placental trophoblast. This beta 1 PAM was used in the
form of pregnancy immune complexes to produce
antibodies by standard hybridoma technology. Five cell
lines were obtained and characterised and two monoclonal
antibodies were chosen for further study based on their
strong binding to cell lines and tissue staining
characteristics.
Lymphocytes have also been obtained from the
drainage of lymph nodes of ovarian cancer patients and
transforming them with Epstein Barr virus to produce
tumour monoclonal antibody secreting lines showing
specificity for ovarian cancer antigens. Fourteen have now
been produced and grown for 9-21 months in continuous
culture. Using fluorescein isothiocyanate, cryostat sections
have been stained with labelled antibody. In the 11
specimens studied so far, binding has been observed in
serous and poorly differentiated adenocarcinoma but not
to mucinous and endometrioid. Clearly, human
monoclonal antibodies have gross advantages over
murine, although there are several problems concerning
EB virus technology, in particular the low level of
antibody produced and the fluctuation in antibody
production. In the discussion which followed, there was
concern expressed about specificity for ovary, but it was
made clear that teratoma and colon specimens have also
been evaluated to date.
An intraperitoneal model for radio-iodinated
monoclonal antibody therapy using the nude mouse was
presented by B. Ward. There is a clear role for immuno-
scintigraphy using i.v. monoclonal antibodies, but not
more than 2% of the injected dose penetrates the tumour,
creating problems for possible therapy. The human
ovarian cancer cell line, JAM, established from a patient
with a poorly differentiated mucinous cystadenocarcinoma
forms subcutaneous and intraperitoneal tumours when
injected into the nude mouse. Ascites which form can be
removed from the mouse and re-established in tissue
culture. All these tumour cells express the HLA-A,B,C
core protein, defined by the monoclonal antibody W6/32
and expressed more strongly in the presence of human
gamma interferon. An HLA Class II determinant, defined
by monoclonal antibody CA2 is not expressed. These 2
antibodies were labelled with 1125 and injected into female
nude mice for distribution studies. Similar results were
found in tumour and non-tumour areas for both specific
and non-specific antibodies. The ascites was checked to
determine whether the antibodies were complexed out
and, using SDS gels, this was found to be the case. Five
of 7 primary tumours formed xenografts of which 3 could
be passaged. Only one did not express the antigens. Dr
Ward felt it to be important, in view of his demonstration
of antigenic modulation, that more basic studies are
performed in mice before considering the treatment of
patients.
The possibility of enhancing the growth of ovarian
tumour cells in vitro by the activity of mesothelial cells
was examined by A. Wilson. It was postulated that
ovarian tumours may depend on growth factors specific to
coelomic sites and the mesothelial cell is unique to the
coelomic cavity. Ascites from ovarian cancer patients was
used as a source of mesothelial cell lines; these retained a
46 X X karyotype and could be passaged 2-3 times before
senescence. Using a bilayered agar culture system,
mesothelial cells have been incorporated as a feeder layer
overlaid with cells from an ovarian cancer cell line OAW
42 and found not only to increase the plating efficiency
but also to increase the number of cells in colonies. The
effect is strongly ratio dependent, as tumour cells in excess
are inhibited. A number of other cell lines were tested
using 10:1 mesothelial/tumour cells. The response was not
found to be specific to ovarian tumour cells or to be
specific to malignancy, as benign tumours can be
stimulated, but 50% primary tumours tested could not.
Using cell free effusions from benign and malignant
tumours, a significant difference was found in their ability
to promote clonogenic growth of normal cells in soft agar.
Preliminary conclusions from this study suggests that the
growth factor from mesothelial cells is unstable and not
specific to malignancy but that the transforming activity
of malignant effusions is greater than that of benign, that
it could be a diagnostic feature and that it may contribute
in vivo to the spread of ovarian cancer. In answer to Drs
Hill, Leake and Simmonds, Dr Wilson confirmed that
activity in mesothelial cells is not consistently
reproducible, but that the cells remain diploid and that
the concentration of transforming growth factor has not
yet been evaluated by bioassay.
B. Hill also presented an in vitro model system for
ovarian cancer using cell lines and primary biopsies as a
means of identifying the optimum scheduling of anti-
tumour drugs. Using the Courtenay clonogenic assay, in
vitro treatment of ascites cells with cis-platinum,
adriamycin or vinblastine generated exponential survival
curves with increasing cell kill, resulting from either
increasing drug concentrations or prolonging exposure
duration. Negligible kill was detected with short exposure
times using hydroxyurea, vincristine or methotrexate,
although continuous exposure to the first two gave
significant cytotoxic effects.
Four ovarian cancer cell lines were then used to
investigate this phenomenon. Cis-platinum and450 A.P. SIMMONDS
adriamycin again demonstrated increased cell kill with
increasing duration of exposure, while vincristine and
etoposide required exposures of up to 24 hours in order to
bring about significant cytotoxic effects. One cell line used
was found to bear some relationship to the original
biopsy material, although the 10 fold decrease in ID50
observed for cis-platinum and adriamycin for the cell line
may be accounted for by its faster doubling time. There
was, however, a marked heterogeneity of response for
adriamycin in biopsy material; this was not observed for
platinum. A cell line SK abc was exposed to increasing
concentrations of adriamycin and a resistant sub-line was
produced over a prolonged period of time in which
resistance was increased 1000 fold. It appears relatively
easy to produce adriamycin resistant cell lines at low
concentrations and the clinical implications of this are
that low doses of adriamycin should not be used for
patients, as these will rapidly generate resistant sub-
populations. In answer to questions from Dr Wiltshaw
and Prof. Fennelly, it was confirmed that there had, as
yet, been little feedback from clinicians concerning this
problem. There was similarly a problem in using radio-
labelled drugs as concentrations of label sufficient to
investigate uptake of drug into resistant cells result in an
overloading of drug. The resistance measured, however, is
stable through subsequent passages.
Patterns of cross resistance in two human ovarian
adenocarcinoma cell lines were examined by J. Lawrie.
PEOl and PEO4 were established from the same patient
before and after the onset of clinical resistance to
platinum, chlorambucil and 5-FU. Both lines grow as
monolayers, are ER and PR negative, but positive for
markers to human milk fat globule protein. Analysis of
sensitivity to drugs received, together with possible cross
resistance to platinum analogues CB DCA, JM 40 and
CHIP was investigated by clonogenic assay on plastic.
Cells were incubated with drug for 72 hours, re-fed at
intervals and colonies counted at 14 days. The ID50
values for the 2 lines to cis-platinum and chlorambucil
measured by 3H TdR uptake showed approximately 3
fold difference, a similar pattern being observed for 5FU.
The range of sensitivity for platinum analogues is higher
than the parent compound and similar patterns are
observed for each line, while JM40 parallels the pattern of
resistance seen with platinum. Chlorambucil shows a
comparable pattern for the 2 lines while adriamycin and
vincristine showed a modest increase in resistance for
PEO4 and no change for mitozantrone. A resistant
subline of PEOl has been developed by exposure to
increasing amounts of platinum and shows an ID50 of 25-
fold increase growing in the absence of drug for 10
passages. Mr Chan suggested that PEOl was already
resistant to drugs and therefore true sensitivity and
resistance were not being compared. In answer to Dr Hill,
it was stated that population doubling time was 22-24
hours and that the mechanisms of resistance were the
topic of a future study. Both karotype and receptors of
PEO1 were checked again at high passage numbers; these
and drug resistance were retained in culture.
A. Simmonds presented a study of the use of the
bilayered agar clonogenic assay as an aid to predicting
clinical outcome in ovarian cancer. The original study
over a 3 year period had studied 200 samples from 106
patients, retaining the original Hamburger and Salmon
culture system using a range of drug concentrations of cis-
platinum adriamycin and cyclophosphainide up to the
peak plasma concentration. In untreated patients 60% of
samples (48% of patients) were markedly sensitive to cis-
platinum and 87% of samples (75% of patients) were
sensitive to adriamycin. Eighty-one per cent of cases
sensitive to adriamycin were also sensitive to cis-platinum.
Seventy per cent of patients were resistant to
cyclophosphamide. Samples from pre-treated patients
demonstrated residual sensitivity in only 20% of cases.
Clinical correlations were made for only 23 patients due
to a combination of low plating efficiency and changes in
patient therapy. In vitro sensitivity to cis-platinum and
adriamycin was related to a good clinical response, but no
correlations were made between resistance to these drugs
in vitro and clinical outcome. There was a striking
relationship, however, between platinum resistance in vitro
and failure to respond to other alkylating agents received
singly.
The culture system was changed to include rat rbc and
drugs tested singly at 10% peak plasma concentration.
Five sequential patient samples received were then
discussed. Four of 5 patients, previously untreated,
demonstrated marked in vitro resistance to alkylating
agents and progressed on regimes based on these
compounds. The fifth patient had relapsed after treatment
with the CAP regime, was resistant in vitro to alkylating
agents and adriamycin and failed to respond to further
treosulphan therapy. In vitro resistance therefore showed
marked correlation with clinical outcome and although
the first study had not shown such a high percentage of
overt resistance in untreated patients, it does correlate
with the clinical experience of poor alkylating agent
response. In answer to questions from Drs Sevin,
Wiltshaw, Blackledge and Prof. Fennelly, it was
confirmed that there had been no stimulation of colony
growth with low dose cis-platinum although cell size in
colonies changed; that a higher percentage of samples
grew in the changed culture system and that it would be
possible to produce a result for clinicians 12 days after
receipt of sample.
A study of cis-platinum time courses in patients and the
concentrations surrounding tumour cells in vivo was
presented by M. Shelley. Platinum and its metabolites
bind firmly to plasma proteins. Informed consent was
obtained from 3 patients with Stage III serous cystadeno-
carcinoma of ovary for whom primary surgical debulking
was not possible. All had a tumour burden of >O1cm
and received platinum 60-100mgm-2 IV over a 6h
infusion with pre and post hydration. Blood samples from
a forearm catheter were taken before during and post
infusion for 24h. Total and ultrafilterable (non protein
bound) values were obtained. Fluid from malignant cysts
was aspirated with a 21 g needle and platinum values
obtained as before, by flameless atomic absorption
spectrophotometry. Peak concentrations of total drug in
plasma were similar (2.28-3.01 pgml-1) but variable
between patients in cystic fluid (0.41-1.72,ugml -1).
Maximum ultrafilterable platinum levels were similar in
both fluids and between patients, but post-infusion,
ultrafilterable levels declined rapidly and were below
detection after 3 hours. The AUCs for ultrafilterable
platinum in the cystic fluids were approximately 50% of
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fluid and with peak levels ranging from 0.30-0.48Mgml-1,
tumour exposure levels (AUC) of 1.15-1.60 pgml-I h-
were obtained. The conclusions from this study were that
tumour exposure to total platinum is variable between
patients but, more importantly, the availability of
pharmacologically active platinum species (ultrafilterable)
is less than has been anticipated previously, thus
confirming 10% peak plasma concentration values as a
reasonable in vitro model test concentration.
This 3 day meeting was wide ranging in topics
and vigorous discussions were pursued following
the presentations. In spite of considerable
optimism, however, about new methods of
diagnosing and monitoring of the disease and the
success of properly administered chemotherapy for
some patient sub-groups, the concensus of the
meeting was that it was the skill and interest of the
surgeon which had the greatest influence on patient
survival and that the benefits of advances in these
former areas would not be realised without more
widespread practice ofcytoreductive surgery.
L